Contents
Cover
Methods and Principles in Medicinal Chemistry
Title Page
Copyright
List of Contributors
Foreword
Preface
A Personal Foreword
Acronyms
Chapter 1: Medicinal Chemistry Approaches to Creating Targeted Medicines
1.1 Introduction
1.2 Role of Medicinal Chemistry in Drug Discovery
1.3 Evolution of Molecular Design for Subsets of Patients
1.4 Combinations for Effective Therapies
1.5 Biomarkers in Targeting Patients
1.6 Emerging Field of Epigenetics
1.7 Systems Chemical Biology
1.8 Theranostics and Designing Drug Delivery Systems
1.9 Rapid Progress in Further Personalizing Medicine Expected
References
Chapter 2: Discovery of Predictive Biomarkers for Anticancer Drugs
2.1 Introduction
2.2 “Oncogene Addiction” as a Paradigm for Clinical Implementation of Predictive Biomarkers
2.3 Cancer Cell Lines as a Model System for Discovery of Predictive Biomarkers
2.4 Modeling Drug Resistance to Discover Predictive Biomarkers
2.5 Discovery of Predictive Biomarkers in the Context of Treatment Combinations
2.6 Discovery of Predictive Biomarkers for Antiangiogenic Agents
2.7 Gene Expression Signatures as Predictive Biomarkers
2.8 Current Challenges in Discovering Predictive Biomarkers
2.9 Future Perspective
References
Chapter 3: Crizotinib
3.1 Introduction
3.2 Discovery of Crizotinib (PF -02341066) [40]
3.3 Kinase Selectivity of Crizotinib
3.4 Pharmacology of Crizotinib [45,46]
3.5 Human Clinical Efficacies of Crizotinib
3.6 Summary
References
Chapter 4: Discovery and Development of Vemurafenib: First-in-Class Inhibitor of Mutant BRAF for the Treatment of Cancer
4.1 Background
4.2 Discovery and Development of Vemurafenib (PLX4032)
4.3 Pharmacology
4.4 Clinical Efficacy and Safety
4.5 Companion Diagnostic (cobas 4800) Development
4.6 Synthesis
4.7 Summary
References
Chapter 5: Targeting Basal-Cell Carcinoma: Discovery and Development of Vismodegib (GDC -0449), a First-in-Class Inhibitor of the Hedgehog Pathway
5.1 Introduction
5.2 Hedgehog and Basal-Cell Carcinoma
5.3 Cyclopamine as an SMO Antagonist
5.4 Small-Molecule Inhibitors of SMO
5.5 Preclinical Characterization of Vismodegib
5.6 Vismodegib Clinical Experience in Phase I
References
Chapter 6: G-Quadruplexes as Therapeutic Targets in Cancer
6.1 Introduction
6.2 Quadruplex Fundamentals
6.3 Genomic Quadruplexes
6.4 Quadruplexes in Human Telomeres
6.5 Quadruplexes as Anticancer Targets – Evidence from In Vivo Studies
6.6 Native Quadruplex Structures
6.7 Quadruplex–Small-Molecule Structures
6.8 Developing Superior Quadruplex-Binding Ligands
6.9 Conclusions
References
Chapter 7: Identifying Actionable Targets in Cancer Patients
7.1 Introduction and Background
7.2 Overview of Genomic Sequencing and Its Impact on the Identification of Actionable Mutations
7.3 Actionable Targets by Clinical Molecular Profiling: the OICR / PMH Experience
7.4 Some Experiences of Other Clinical Oncology Molecular Profiling Studies
7.5 Identifying Secondary and Novel Mutations through Molecular Profiling
7.6 Understanding and Targeting Resistance Mutations: a Challenge and an Opportunity for NGS
7.7 Concluding Remarks and Future Perspectives
References
Chapter 8: DNA Damage Repair Pathways and Synthetic Lethality
8.1 Introduction
8.2 DNA Damage Response
8.3 Synthetic Lethality
8.4 Lead Case Study: PARP Inhibitors
8.5 Additional Case Studies
8.6 Screening for Synthetic Lethality
8.7 Contextual Synthetic Lethality Screening
8.8 Cancer Stem Cells
8.9 Conclusions and Future Directions
References
Chapter 9: Amyloid Chemical Probes and Theranostics: Steps Toward Personalized Medicine in Neurodegenerative Diseases
9.1 Introduction
9.2 Amyloid Plaques as the Biomarker in AD
9.3 Detecting Amyloid Plaques in Patients: from A lois A lzheimer to A myvid and Beyond
9.4 Same Causes, Same Imaging Agents?
9.5 Theranostics in AD
9.6 Conclusions and Perspectives
References
Chapter 10: From Human Genetics to Drug Candidates: An Industrial Perspective on LRRK2 Inhibition as a Treatment for Parkinson's Disease
10.1 Introduction
10.2 Biochemical Studies of LRRK 2 Function
10.3 Cellular Studies of LRRK 2 Function
10.4 Animal Models of LRRK 2 Function
10.5 Clinical Studies of LRRK 2-Associated PD and Future Prospects
10.6 Small-Molecule Inhibitors of LRRK 2
10.7 Structural Models of the LRRK 2 Kinase Domain
10.8 Strategies Used to Identify LRRK 2 Kinase Inhibitors (Overview)
10.9 Conclusions
References
Chapter 11: Therapeutic Potential of Kinases in Asthma
11.1 Introduction
11.2 Mitogen-Activated Protein Kinases
11.3 Nonreceptor Protein Tyrosine Kinases
11.4 Receptor Tyrosine Kinases
11.5 Phosphatidylinositol-3 Kinases
11.6 AGC Kinases
11.7 IκB Kinase
11.8 Other Kinases
11.9 Conclusions: Future Directions
References
Chapter 12: Developing Targeted PET Tracers in the Era of Personalized Medicine
12.1 Imaging and Pharmacodynamics Biomarkers in Drug Development
12.2 General Considerations for Development of 11C- and 18F-labeled PET Tracers
12.3 Radiolabeling Compounds with 11C
12.4 Radiolabeling Compounds with 18F
12.5 PET Imaging in the Clinic, Research, and Drug Development
12.6 PET Tracer Kinetic Modeling for Quantification of Tracer Uptake
12.7 Concluding Remarks
References
Chapter 13: Medicinal Chemistry in the Context of the Human Genome
13.1 Introduction
13.2 Drugs Targeting Kinases
13.3 Drugs Targeting Phosphatases
13.4 In silico -Based Lead Discovery in the GPCR Family
13.5 Targeting Epigenetic Regulation: Histone Demethylases
13.6 Targeting Epigenetic Regulation: Histone Deacetylases
13.7 A Family-Wide Approach to Poly(ADP -Ribose) Polymerases
13.8 Future Drug Target Superfamilies: Ubiquitination and Deubiquitination
13.9 Summary and Outlook
References
Index
Methods and Principles in Medicinal Chemistry
Edited by R. Mannhold, H. Kubinyi, G. Folkers
Editorial Board
H. Buschmann, H. Timmerman, H. van de Waterbeemd, T. Wieland
Previous Volumes of this Series:
Brown, Nathan (Ed.)
Scaffold Hopping in Medicinal Chemistry
2014
ISBN: 978-3-527-33364-6
Vol. 58
Hoffmann, Rémy D. / Gohier, Arnaud / Pospisil, Pavel (Eds.)
Data Mining in Drug Discovery
2014
ISBN: 978-3-527-32984-7
Vol. 57
Dömling, Alexander (Ed.)
Protein-Protein Interactions in Drug Discovery
2013
ISBN: 978-3-527-33107-9
Vol. 56
Kalgutkar, Amit S. / Dalvie, Deepak / Obach, R. Scott / Smith, Dennis A.
Reactive Drug Metabolites
2012
ISBN: 978-3-527-33085-0
Vol. 55
Brown, Nathan (Ed.)
Bioisosteres in Medicinal Chemistry
2012
ISBN: 978-3-527-33015-7
Vol. 54
Gohlke, Holger (Ed.)
Protein-Ligand Interactions
2012
ISBN: 978-3-527-32966-3
Vol. 53
Kappe, C. Oliver / Stadler, Alexander / Dallinger, Doris
Microwaves in Organic and Medicinal Chemistry
Second, Completely Revised and Enlarged Edition
2012
ISBN: 978-3-527-33185-7
Vol. 52
Smith, Dennis A. / Allerton, Charlotte / Kalgutkar, Amit S. / van de Waterbeemd, Han / Walker, Don K.
Pharmacokinetics and Metabolism in Drug Design
Third, Revised and Updated Edition
2012
ISBN: 978-3-527-32954-0
Vol. 51
De Clercq, Erik (Ed.)
Antiviral Drug Strategies
2011
ISBN: 978-3-527-32696-9
Vol. 50
Klebl, Bert / Müller, Gerhard / Hamacher, Michael (Eds.)
Protein Kinases as Drug Targets
2011
ISBN: 978-3-527-31790-5
Vol. 49
All books published by Wiley-VCH are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.
Library of Congress Card No.: applied for
British Library Cataloguing-in-Publication Data A catalogue record for this book is available from the British Library.
Bibliographic information published by the Deutsche Nationalbibliothek The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at <http://dnb.d-nb.de>.
© 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Boschstr. 12, 69469 Weinheim, Germany
All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.
Print ISBN: 978-3-527-33394-3
ePDF ISBN: 978-3-527-67728-3
ePub ISBN: 978-3-527-67727-6
Mobi ISBN: 978-3-527-67726-9
oBook ISBN: 978-3-527-67725-2
List of Contributors
Rima Al-awar
Ontario Institute for Cancer Research
MaRS Centre
101 College Street
Toronto, ON M5G 0A3
Canada
Lisa D. Belmont
Genentech Inc.
Oncology Diagnostics
MS 411A, 1 DNA Way
South San Francisco, CA 94080
USA
Gideon Bollag
Plexxikon Inc.
Research
91 Bolivar Drive
Berkeley, CA 94710
USA
Maria Laura Bolognesi
Dipartimento di Farmacia e
Biotecnologie
Via Belmeloro, 6
40126 Bologna, Italy
Italy
Richard Bourgon
Genentech Inc.
Oncology Bioinformatics
MS 411A, 1 DNA Way
South San Francisco, CA 94080
USA
Andrew M.K. Brown
Ontario Institute for Cancer Research
MaRS Centre
101 College Street
Toronto, ON M5G 0A3
Canada
Andreas Brunschweiger
Technische Universität Dortmund
Fakultät Chemie
Chemische Biologie
Otto-Hahn-Strasse 6
44227 Dortmund
Germany
Huifen Chen
Genentech Inc.
Discovery Chemistry
1 DNA Way
South San Francisco, CA 94080
USA
William Cho
Genentech Inc.
Early Clinical Development
1 DNA Way
South San Francisco, CA 94080
USA
Jean Cui
Pfizer Worldwide Research and Development
La Jolla Laboratories
Cancer Chemistry
10770 Science Center Drive
San Diego, CA 92121
USA
Janet Dancey
Ontario Institute for Cancer Research
MaRS Centre
101 College Street
Toronto, ON M5G 0A3
Canada
Martin P. Edwards
Pfizer Worldwide Research and Development
La Jolla Laboratories
Cancer Chemistry
10770 Science Center Drive
San Diego, CA 92121
USA
Anthony A. Estrada
Genentech Inc.
Discovery Chemistry
1 DNA Way
South San Francisco, CA 94080
USA
Marie Evangelista
Genentech Inc.
Oncology Diagnostics
MS 411A, 1 DNA Way
South San Francisco, CA 94080
USA
Gaston Habets
Plexxikon Inc.
Assay & Screening
91 Bolivar Drive
Berkeley, CA 94710
USA
Jonathan Hall
ETH Zürich
Institute of Pharmaceutical Sciences
Wolfgang-Pauli-Str. 10
8093 Zürich
Switzerland
Xiaodong Huang
Genentech Inc.
Oncology Diagnostics
MS 411A, 1 DNA Way
South San Francisco, CA 94080
USA
Prabha Ibrahim
Plexxikon Inc.
Non-Clinical Development
91 Bolivar Drive
Berkeley, CA 94710
USA
Robert S. Kania
Pfizer Worldwide Research and Development
La Jolla Laboratories
Cancer Chemistry
10770 Science Center Drive
San Diego, CA 92121
USA
Karen Lackey
JanAush LLCCharleston, SC 29425USA
Dramane Lainé
Hoffmann-La Roche, Inc.
340 Kingsland Street
Nutley, NJ 07110
USA
Francisco Lopez-Tapia
Hoffmann-La Roche, Inc.
340 Kingsland Street
Nutley, NJ 07110
USA
Matthew Lucas
Hoffmann-La Roche, Inc.
340 Kingsland Street
Nutley, NJ 07110
USA
Stephen Lynch
Hoffmann-La Roche, Inc.
340 Kingsland Street
Nutley, NJ 07110
USA
Jan Marik
Genentech, Inc.
Biomedical Imaging
1 DNA Way
South san Francisco, CA 94080
USA
James C. Marsters Jr.
Genentech Inc.
PM & O
1 DNA Way, MS 16a
South San Francisco, CA 94080
USA
John McPherson
Ontario Institute for Cancer Research
MaRS Centre
101 College Street
Toronto, ON M5G 0A3
Canada
Stephen Neidle
University College London
School of Pharmacy
29-39 Brunswick Square
London WC1N 1AX
UK
Richard M. Neve
Genentech Inc.
Discovery Oncology
MS 411A, 1 DNA Way
South San Francisco, CA 94080
USA
Bruce D. Roth
Genentech Inc.
Discovery Chemistry
1 DNA Way
South San Francisco, CA 94080
USA
Sandra M. Sanabria Bohorquez
Genentech, Inc.
Clinical Imaging Group
1 DNA Way
South san Francisco, CA 94080
USA
Maike Schmidt
Genentech Inc.
Oncology Diagnostics
MS 411A, 1 DNA Way
South San Francisco, CA 94080
USA
Jeffrey Settleman
Genentech Inc.
Discovery Oncology
MS 411A, 1 DNA Way
South San Francisco, CA 94080
USA
Zachary K. Sweeney
Novartis
Global Discovery Chemistry
4560 Horton St.
Emeryville, CA 94608-2916
USA
James Tsai
Plexxikon Inc.
Pharmacology
91 Bolivar Drive
Berkeley, CA 94710
USA
David Uehling
Ontario Institute for Cancer Research
MaRS Centre
101 College Street
Toronto, ON M5G 0A3
Canada
Nicholas van Bruggen
Genentech, Inc.
Biomedical Imaging
1 DNA Way
South san Francisco, CA 94080
USA
Simon Ward
Translational Drug Discovery Group, University of Sussex, Brighton, BN1 9QJ, UK
Harvey Wong
Genentech Inc.
Drug Metabolism and Pharmacokinetics
1 DNA Way, MS 16a
South San Francisco, CA 94080
USA
Robert L. Yauch
Genentech Inc.
Oncology Diagnostics
MS 411A, 1 DNA Way
South San Francisco, CA 94080
USA
Chao Zhang
Plexxikon Inc.
Informatics & Structural Chemisty
91 Bolivar Drive
Berkeley, CA 94710
USA
Jiazhong Zhang
Plexxikon Inc.
Chemistry
91 Bolivar Drive
Berkeley, CA 94710
USA
Haitao Zhu
Genentech Inc.
Neuroscience
1 DNA Way
South San Francisco, CA 94080
USA
Foreword
Over the past decade, major advances have been made in elucidating the pathophysiological processes involved in many human diseases, including solid and hematological malignancies, hepatitis C, asthma, Alzheimer's disease, Parkinson's disease, age-related macular edema, and even diabetes. We know more about the biology of human disease than ever before, yet most diseases are still classified by their clinical presentation, associated physical exam, imaging data, and laboratory abnormalities. Only a few diseases are defined by the molecular pathways that cause the disease.
Using a “clinically” oriented approach to medicine results in profound heterogeneity in the molecular underpinnings of a given disease. Compounding this problem is that this heterogeneity has traditionally not been taken into account when studies were designed to evaluate a new molecular entity in a given disease. As an example, in 2005, Peagram et al. performed a Medline literature search using the keyword “epidermal growth factor receptor” (EGFR) and found 13 569 citations. Despite this intense level of scientific investigation into the EGFR, it was not until 2004 that important mutations in the kinase domain of the EGFR that identifies patients who are particularly sensitive to the effects of small-molecule tyrosine kinase inhibitors such as gefitinib or erlotinib were first reported. This lack of insight contributed to the numerous failed studies in the frontline non-small cell lung cancer setting when these inhibitors were given to an all-comers population. The authors of this paper also performed simulations to model the impact of including patients in a clinical trial whose disease is not sensitive to a given drug's treatment effect. They simulated administering a highly effective treatment to women with newly diagnosed metastatic breast cancer and found that when a diagnostic was used to select those patients most likely to benefit, the clinical trial was robustly positive. When the percentage of patients who would not benefit was increased, the treatment effect waned. Importantly, if only 25% of patients benefited (as is roughly the case with Herceptin for women with Her2 overexpressing breast cancer), studying an unselected population in a clinical trial (i.e., where 75% are unlikely to benefit) would result in survival curves that are essentially overlapping. In other words, without appreciating this heterogeneity in disease biology, a clinical trial evaluating a potentially important new therapy would be negative without a diagnostic to identify those most likely to benefit.
The pharmaceutical industry is under intense pressure to improve R&D productivity. This is in large part driven by increasing costs associated with conducting clinical trials compounded by very low success rates once a drug enters clinical testing. One cannot help but wonder how many of the over 90% of drugs that fail during clinical development would have succeeded had more attention been given to identifying the population most likely to benefit.
Fortunately, over the past decade and in particular the last several years, there has been a marked shift in the discovery and development process to incorporate these concepts. Advances in cellular and molecular biology, human genetics, translational medicine (including biomarkers and diagnostics), and innovative clinical trials designs have enabled us to enter the era of so-called personalized health care (PHC). This is leading to some of the most promising new therapies ever developed in the history of medicine. In oncology alone, this new era of medicine has resulted in numerous new drugs for patients. As of 2013, the NCI website has identified over 40 “targeted therapies,” although not all of these new medicines would meet the strict definition described above.
For some of these new therapies, we have observed treatment effects of almost unparalleled nature, a shorter time in clinical development, and although it is still in early days, it appears that the success rates are also likely to exceed industry averages.
It should also be pointed out that while the advances in personalized health care have been extremely impressive in oncology drug development, a similar targeted strategy is being embraced in the fields of immunology, neuroscience, and other areas of medicine. It should also be highlighted that while for most areas of medicine PHC is only recently being embraced, the field of infectious disease has adopted this concept for decades. The idea that all cases of “pneumonia” are not the same is today taken for granted. The technology for understanding the pathophysiology of this disease required much less sophisticated tools (i.e., the microscope and Petri dishes). This leads to subclassification of pneumonia by the causal agent with different treatments being prescribed based on the presumed organism responsible for the disease.
With the sequencing of the human genome over a decade ago and an increasingly sophisticated understanding of the pathophysiology of human disease-based metabolomics, proteomics, and other tools, we have clearly ushered in a new era in drug discovery and development. The end result is likely to have a very meaningful and lasting impact on academia, biotechnology and pharmaceutical companies, payers, health care providers, and most importantly patients.
Surprisingly, despite the importance of personalized health care in so many recent advances in drug therapy, there have been few attempts to collect the success stories across industry and academia that have advanced research toward new, targeted therapies. This book, therefore, fills this gap in the literature and thus should be a useful resource for pharmaceutical and biopharmaceutical researchers for years to come.
Executive Vice President, Global Product Development Chief Medical Officer Genentech Inc., 1 DNA Way South San Francisco, CA 94080
Hal Barron, MD
F. Hoffmann-La Roche Ltd.
Preface
The notion of personalized medicine, in both the laity and the scientific community, is very often associated with screening, genetic profiling, and risk stratification. While it is unquestioned that genomics is the starting point of future “targeted medicine,” personal genomics and individual genetic testing for risk stratification are still under public debate, because of their ethical and legal implications. Therefore, an account of how all this collected genetic information translates into therapeutic practice and how it may do so in near future is of highest importance not only for the public dialogue but also for the experts in drug design and development.
This book provides such an account. Edited by Karen Lackey and Bruce D. Roth, both fundamentally involved in the topic, the book convenes experts from the medicinal chemistry field in the private sector and the academia to provide their perspectives on personalized medicine. Naturally, the scope is broad. The book consisting of 13 chapters covers a more general content on feasibility of medchem approaches, contrasted by those that describe case studies of successful implementations and also others that open up new field to explore. In addition to cancer – the therapeutic area one would expect to have been mainly covered, neurodegenerative diseases such as Alzheimer's and Parkinson's diseases as well as asthma have also been studied in this book. Methodological approaches and targets besides “chemistry” range from molecular profiling, G-quadruplexes, amyloid probes, and PET to histones, plaques in the brain, kinases, ubiquination as a future target superfamily, and DNA repair pathways.
Of course, any book on this broad topic cannot be comprehensive or even encyclopedic. The translational process of personalized medicine is in full swing and many economical questions either for the private sector or for patients and social security systems remain to be solved.
The book parallels success stories – that have been long overdue to be reported – with recent and future developments in the field.
In this respect, it is not only at cutting edge in the field but also fulfills in an excellent way the requirement of this series to serve as a handbook for bench chemists, developers, and the academic realm of research and teaching. Especially teachers may feel encouraged to use the eminent expert information collected, to challenge their students with this extension in medicinal chemistry to a medicine of the future.
The series editors are indebted to the authors and the editors who made it possible to cover this very essential issue.
We are also very much indebted to Heike Nöthe and Frank Weinreich, both at Wiley-VCH. Their support and ongoing engagement not only for this book but also for the whole series Methods and Principles in Medicinal Chemistry greatly contribute to the success of this excellent collection related to drug research.
Düsseldorf
Weisenheim am Sand
Zürich
October 2013
Raimund Mannhold
Hugo Kubinyi
Gerd Folkers
A Personal Foreword
Personalized medicine and personalized healthcare have become virtual buzzwords used by the lay press and the pharmaceutical and biopharmaceutical industries in describing their current approaches to drug discovery and development aimed at providing patients with individualized therapies. Many established and emerging companies have even suggested that this is the foundation for their business strategy. Fundamentally, creating personalized medicine requires the integration of multiple disciplines, including medicinal chemistry, genetics, diagnostics, biochemistry, cellular biology, pharmacology, formulations, and clinical sciences, in order to ensure that patients have access to and are prescribed medicines with the highest likelihood of effectively treating their specific disease – and that patients unlikely to respond are not given drugs from which they will likely not receive benefit. The ultimate goal of the medical field is to have drugs that treat the underlying causes of the disease pathology. This approach has many benefits: to the companies, lower costs and higher success rates; for the patients, more effective therapies with better risk/benefit ratios. In fact, over the last several decades, many drugs, both small molecules and biologics, have been discovered and developed that would fall under this umbrella, especially in the treatment of cancer, where the emphasis on personalized medicine has led to greatly improved success rates in bringing new medicines to the market. Despite this emphasis on personalized medicine in the last decade, there has been no comprehensive treatment of this subject focusing specifically on the role of the medicinal chemist in this process, despite the fact that virtually all small-molecule drugs originate in the mind of the medicinal chemist.
In this book, we have attempted to bring together the collective experience of the pharmaceutical industry and academia, across multiple therapeutic areas and disciplines, in an attempt to capture the full spectrum of activities in implementing personalized medicine. Thus, we have chapters providing case studies of several recently approved “targeted therapies” in oncology where personalized medicine is most mature, but there are also chapters that cover developments in other therapeutic areas, development of diagnostics, imaging, and several on different aspects of new target discovery. Our hope is that this book will not only be a useful review of past practices in the discovery and development of personalized medicine but will also lay the foundation for future advances in bringing life-changing, transformative medicines to patients. Ultimately, the goal of all of those who have committed their lives and energies to medicinal sciences is to bring benefit to the patients who are desperately waiting for the drugs that arise from the incredible scientific discoveries emanating from the work of these dedicated researchers.
Finally, we would like to thank all of the more than 40 authors and contributors to this book as well as the support and encouragement of Dr Heike Nöthe and Dr Frank Weinreich of Wiley-VCH. We are also greatly indebted to Ms Christine Cumberton for the finalization and compilation of chapters for submission to the publisher.
Nutley, NJ
South San Francisco, CA
June 2013
Karen Lackey
Bruce D. Roth
Acronyms
AChE(I) |
acetylcholine esterase (inhibitor) |
AD |
Alzheimer's disease |
ADC |
antibody drug conjugates |
ADME |
absorption, distribution, metabolism, and excretion |
AE |
adverse events |
AGC |
protein kinase A, G, and C families |
AHR |
airway hyperresponsiveness |
ALCL |
anaplastic large-cell lymphoma |
ALK |
anaplastic lymphoma kinase |
AP-1 |
activating protein 1 |
APC |
adenomatous polyposis coli gene |
APP |
amyloid precursor protein |
ATP |
adenosine triphosphate |
AUC |
area under the curve |
BBB |
blood–brain barrier |
BCC |
basal-cell carcinoma |
BCRP |
breast cancer resistance protein |
BER |
base excision repair |
BID |
bis in die (Latin) meaning twice a day |
BP |
binding protein |
CAD |
coronary artery disease |
CBD |
corticobasal degeneration |
CETP |
cholesteryl ester transfer protein |
CHMP |
Committee for Medicinal Products for Human Use |
CIA |
collagen-induced arthritis |
CI |
confidence interval |
CLR |
clearance rate |
CML |
chronic myelogenous leukemia |
CNS |
central nervous system |
CNV |
copy number variations |
COPD |
chronic obstructive pulmonary disorder |
CR |
complete response |
CRC |
colorectal cancer |
CSF |
cerebral spinal fluid |
CTC |
circulating tumor cells |
CUP |
carcinoma of unknown primary |
CDK |
cyclin-dependent kinase |
COMT |
catechol-O-methyl transferase |
DAG |
diacylglycerol |
DAT |
dopamine transporter |
DCR |
disease control rate |
DDR |
DNA damage response |
DECP |
diethyl cyanophosphonate |
DLB |
dementia with Lewy bodies |
DMF |
dimethylformamide |
DMSO |
dimethylsulfoxide |
DNA |
deoxyribonucleic acid |
DR |
direct repair |
DUPA |
(dicarboxypropyl)ureidopentanedioic acid |
ER |
estrogen receptor |
ErbB2 |
erythroblastic leukemia oncogene homolog 2, also known as HER2/Neu |
ERK |
extracellular regulating kinase |
FAM |
6-carboxyfluorescein |
FBDD |
fragment-based drug discovery |
FBLD |
fragment-based ligand discovery |
FDA |
Food and Drug Administration |
FDG |
fluoro-deoxy-d-glucose |
FFPET |
formalin fixed paraffin embedded tissue |
FISH |
fluorescence in situ hybridization |
FRET |
fluorescence resonance energy transfer |
FTD |
frontotemporal dementia |
GEMM |
genetically engineered mouse model |
GIM |
genetic interaction mapping |
GIST |
gastrointestinal stromal tumors |
GLUT |
glucose transport proteins |
GSK |
glycogen synthase kinase |
GTPase |
guanine triphosphatase |
GWAS |
genome-wide association studies |
HDAC |
histone deacetylases |
HDM |
histone demethylases |
HER2 |
human epidermal growth factor receptor 2 |
hERG |
human ether-a-go-go related gene |
HGF(R) |
hepatocyte growth factor (receptor) |
Hh |
hedgehog |
HIF |
hypoxia inducible factor |
HR |
homologous recombinations |
HSP |
heat shock protein |
HTS |
high-throughput screening |
IC50
|
concentration at 50% inhibition |
ICGC |
International Cancer Genome Consortium |
ICS |
inhaled corticosteroids |
IGF(R) |
insulin growth factor (receptor) |
IHC |
immunohistochemistry |
IL-1 |
interleukin-1 |
IMT |
inflammatory myofibroblastic tumors |
INDEL |
insertions or deletions of a short coding region |
ITK |
interleukin-2-inducible T-cell kinase |
IV |
intravenous |
LABA |
long acting beta-2 agonists |
LE |
ligand efficiency |
LipE |
lipophilic efficiency |
LN |
lymph node |
MAO |
monoamine oxidase |
MAPK |
mitogen-activated protein kinase |
MBC |
metastatic breast cancer |
MBP |
microprecipitated bulk powder |
MCI |
mild cognitive impairment |
MCT |
methylcellulose Tween |
MGMT |
O-(6)-methylguanine-DNA methyltransferase |
MK |
midkine |
MLC |
myosin light chain |
MLK |
mixed lineage kinase |
MMR |
mismatch repair |
MMSE |
minimental state examination |
MOM |
methoxymethyl |
MP |
molecular profiling |
MPI |
myocardial perfusion imaging |
MRI |
magnetic resonance imaging |
MRT |
mean residence time |
MTD |
maximum tolerated dose |
MTEB |
metabotropic glutamate receptor type |
mTOR |
mammalian target of rapamycin |
NA |
not applicable |
NCI |
National Cancer Institute |
NER |
nucleotide excision repair |
NET |
norepinephrine transporter |
NFT |
neurofibrillary tangles |
NGS |
next-generation sequencers |
NHEJ |
nonhomologous end joining |
NHL |
non-Hodgkin lymphoma |
NIH |
National Institute of Health |
NK |
natural killer |
NME |
new molecular entity |
NMR |
nuclear magnetic resonance |
NOAEL |
no adverse effect level |
NPM |
nucleophosmin |
NRTK |
nonreceptor tyrosine kinase |
NSCLC |
non-small cell lung cancer |
OICR |
Ontario Institute for Cancer Research |
ORR |
overall response rate |
OS |
overall survival |
PARP |
poly-ADP-ribose polymerase |
PAS |
peripheral anionic site |
PBCA |
poly(butyl-2-cyanoacrylate) |
PCR |
polymerase chain reaction |
PD |
pharmacodynamic or progressive disease or Parkinson's disease |
PDAC |
pancreatic cancer-ductal adenocarcinoma |
PDB |
Protein Data Bank |
PDGF(R) |
platelet-derived growth factor (receptor) |
PEG |
polyethyleneglycol |
PET |
positron emission tomography |
PFS |
progression free survival |
PI3K |
phosphoinositol 3 kinase |
PiB |
Pittsburgh compound-B |
PK |
pharmacokinetics |
PLGA |
poly(dl-lactide-co-glycolide) |
PMD |
protein misfolding diseases |
PSMA |
prostate-specific membrane antigen |
PSP |
progressive supranuclear palsy |
PTM |
posttranslational modifications |
PTN |
pleiotrophin |
QSAR |
quantitative structure-activity relationship |
RECISTs |
response evaluation criteria in solid tumors |
RGD |
arginine glycine asparagine |
ROC |
Ras/GTPase domain in complex proteins |
ROCK |
Rho-associated coiled coil containing protein kinase |
RPLN |
retroperitoneal lymph node |
RTK |
receptor tyrosine kinase |
SAR |
structure–activity relationship |
SBS |
sequencing by synthesis |
SD |
standard deviation |
SF |
scatter factor |
SGA |
synthetic genetic array |
SGC |
Structural Genomics Consortium |
SiFA |
silicon-based fluoride acceptors |
siRNA |
small interfering ribonucleic acid |
SLAM |
synthetic lethal analysis by microarray |
SMI |
small-molecule inhibitor |
SMO |
smoothened receptor |
SNP |
single-nucleotide polymorphism |
SPECT |
single-photon emission computed tomography |
SphK |
sphingosine kinase |
SPR |
surface plasmon resonance |
STK |
serine threonine kinase |
Syk |
spleen tyrosine kinase |
TAC |
time activity curve |
TAMRA |
6-carboxytetramethylrhodamine |
TBAF |
tetrabutylammonium fluoride |
TBI |
traumatic brain injury |
TERRA |
telomeric repeat-containing RNA |
TET |
ten-eleven translocation |
ThT |
thioflavin-T |
TKI |
tyrosine kinase inhibitor |
TKL |
tyrosine kinase-like |
TNF |
tumor necrosis factor |
US |
United States |
UV |
ultraviolet |
VEGF(R) |
vascular endothelial growth factor (receptor) |
VMAT |
vesicular monoamine transporter |
W3C |
World Wide Web Consortium |
WES |
whole-exome sequencing |